Tech Transfer Roundup: Inside Merck’s Approach To Academic Partnering
Executive Summary
With later-stage in-licensing assets becoming harder to find, Merck is seeking to work more often and in varied ways with academic and institutional researchers to advance its pipeline. Recent tech transfer deals include Cancer Research UK’s transactions with ProNAi and Artios.
You may also be interested in...
Deal Watch: Genentech Out-Licenses PI3K Inhibitor To Novogen
The Australian firm also buys out Glioblast to add to its capabilities in brain cancer. Meanwhile, India’s Sun Pharmaceutical acquires Auven’s Ocular Technologies, and GlaxoSmithKline partners with Fimbrion in urinary tract infections and with Zai Lab in autoimmune disorders.
Lilly Targets Aduhelm With Aggressive Plans For Donanemab In Alzheimer’s
Lilly plans a head-to-head study of donanemab versus Biogen’s Aduhelm to see which clears amyloid plaque better and has begun a rolling BLA toward accelerated approval of the Alzheimer’s drug.
Financing Quarterly Statistics, Q3 2021
For the third quarter of 2021, biopharmas brought in an aggregate $17.4bn in financing and device company fundraising totaled $3.4bn; while in vitro diagnostic firms and research tools players raised $2.5bn.